CS 834

orally active carbapenem; structure in first source; an ester-type prodrug of R-95867

Also Known As:

CS-834; pivaloyloxymethyl 6-(1-hydroxyethyl)-1-methyl-2-(5-oxopyrrolidin-3-ylthio)-1-carbapen-2-em-3-carboxylate

Networked: 7 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Carbapenems: 4837
        CS 834: 7
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Carbapenems: 4837
        CS 834: 7

Experts

1.	Fukuhara, Hiroshi: 2 articles (12/2003 - 12/2002)
2.	Hata, Tadashi: 2 articles (12/2003 - 12/2002)
3.	Kobayashi, Katsuhiro: 2 articles (12/2003 - 12/2002)
4.	Ohashi, Yuji: 2 articles (12/2003 - 12/2002)
5.	Kawamoto, Isao: 1 article (12/2002)
6.	Sekine, Akiko: 1 article (12/2002)
7.	Uekusa, Hidehiro: 1 article (12/2002)

Related Diseases

1.	Infections 03/01/1998 - "In murine respiratory infection models, the efficacy of CS-834 reflected not only its potent in vitro activity but also the high levels present in the lungs." 12/01/1997 - "The in vivo efficacy of CS-834 was evaluated in murine systemic infections caused by 16 strains of gram-positive and -negative pathogens. " 10/01/1998 - "Against systemic infections in mice caused by various bacteria, CS-834 showed an excellent protective effect and its in-vivo efficacy correlated well with the in-vitro activity of R-95867. " 12/01/1997 - "The efficacy of CS-834 was in many cases superior to those of cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil, especially against infections caused by S. "
2.	Pneumonia (Pneumonitis) 01/01/1998 - "Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice." 12/01/1997 - "Among the drugs tested, CS-834 showed the highest efficacy against experimental pneumonia in mice caused by penicillin-resistant S. " 01/01/1998 - "The efficacy of CS-834, a novel oral carbapenem, was assessed by using a murine model of pneumonia caused by penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and was compared with those of oral cephems, i.e., cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil. "
3.	Sepsis (Septicemia) 03/01/1998 - "Against methicillin-resistant staphylococci, enterococci, Serratia marcescens, Burkholderia cepacia, Stenotrophomonas maltophilia, and Acinetobacter calcoaceticus, R-95867 showed activity comparable to or slightly less than that of imipenem, with MIC90s ranging from 2 to >128 microg/ml. The in vivo efficacy of oral CS-834 against experimental mouse septicemia caused by gram-positive and gram-negative bacteria was better than that of comparative drugs. "
4.	Bacterial Infections (Bacterial Infection) 10/01/1998 - "These results suggest that CS-834 may be effective in the therapy of various bacterial infections."
5.	Urinary Tract Infections (Urinary Tract Infection) 03/01/1999 - "CS-834, a carbapenem antibiotic from Sankyo, is in phase II clinical trials for respiratory and urinary tract infections. "

Related Drugs and Biologics

1.	Penicillins (Penicillin)
2.	Cefpodoxime Proxetil (Vantin)
3.	Cefdinir (Omnicef)
4.	cefditoren pivoxil (Spectracef)
5.	cefteram pivoxil
6.	Carbapenems (Carbapenem Antibiotics)
7.	R 95867
8.	Imipenem
9.	Anti-Bacterial Agents (Antibiotics)
10.	1 beta-methylcarbapenem

Related Therapies and Procedures

1.	Therapeutics